### Title

Asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium

# Keywords

Monkeypox, asymptomatic, subclinical, transmission, infectiousness, epidemic

### Authors:

De Baetselier Irith\*, Van Dijck Christophe\*, Kenyon Chris, Coppens Jasmine, Van den Bossche Dorien, Smet Hilde, Laurens Liesenborghs, Vanroye Fien, Tessa de Block, Florence Eric, Vercauteren Koen\*\*, Van Esbroeck Marjan\*\*\* for the Monkeypox study group

| First Name  | Surname       | Title                                   | Email                 | Affiliation(s)   |
|-------------|---------------|---|-----------------------|--|
| rith*       | De Baetselier | PhD <u>idebaetselier@itg.be</u> Departm |                       | Department of Clinical Sciences, Institute of Tropical Medicine,     |
|             |               |   |                       | Antwerp, Belgium   |
| Christophe* | Van Dijck     | MD                                      | cvandijck@itg.be      | (1) Department of Clinical Sciences, Institute of Tropical Medicine, |
|             |               |   |                       | Antwerp, Belgium   |
|             |               |   |                       | (2) Laboratory of Medical Microbiology, University of Antwerp,       |
|             |               |   |                       | Belgium  |
| Chris       | Kenyon        | PhD                                     | ckenyon@itg.be        | (1) Department of Clinical Sciences, Institute of Tropical Medicine, |
|             |               | MD                                      |                       | Antwerp, Belgium   |
|             |               |   |                       | (2) Division of Infectious Diseases and HIV Medicine, University of  |
|             |               |   |                       | Cape Town, Cape Town, South Africa                                   |
| Jasmine     | Coppens       | PhD                                     | jcoppens@itg.be       | Department of Clinical Sciences, Institute of Tropical Medicine,     |
|             |               |   |                       | Antwerp, Belgium   |
| Dorien      | Van den       | MD                                      | dvandenbossche@itg.be | Department of Clinical Sciences, Institute of Tropical Medicine,     |
|             | Bossche       |   |                       | Antwerp, Belgium   |
| Hilde       | Smet          | BSc                                     | hsmet@itg.be          | Department of Clinical Sciences, Institute of Tropical Medicine,     |
|             |               |   |                       | Antwerp, Belgium   |
| Laurens     | Liesenborghs  | PhD                                     | lliesenborghs@itg.be  | Department of Clinical Sciences, Institute of Tropical Medicine,     |
|             |               | MD                                      |                       | Antwerp, Belgium   |
| Fien        | Vanroye       | MSc                                     | fvanroye@itg.be       | Department of Clinical Sciences, Institute of Tropical Medicine,     |
|             |               |   |                       | Antwerp, Belgium   |
| Tessa       | de Block      | BSc                                     | tdeblock@itg.be       | Department of Clinical Sciences, Institute of Tropical Medicine,     |
|             |               |   |                       | Antwerp, Belgium   |
| Antonio     | Rezende       | PhD                                     | Arezende@itg.be       | Department of Clinical Sciences, Institute of Tropical Medicine,     |
|             |               |   |                       | Antwerp, Belgium   |
| Eric        | Florence      | PhD                                     | eflorence@itg.be      | Department of Clinical Sciences, Institute of Tropical Medicine,     |
|             |               | MD                                      |                       | Antwerp, Belgium   |
| Koen **     | Vercauteren   | PhD                                     | kvercauteren@itg.be   | Department of Clinical Sciences, Institute of Tropical Medicine,     |
|             |               |   |                       | Antwerp, Belgium   |
| Marjan **   | Van Esbroeck  | MD                                      | mvesbroeck@itg.be     | Department of Clinical Sciences, Institute of Tropical Medicine,     |
|             |               |   |                       | Antwerp, Belgium   |

# Monkeypox study group

| First Name | Surname       | Title                                     | Email                     | Affiliation(s)   |  |
|------------|---------------|---|---------------------------|--|--|
| Kadrie     | Ramadan       | BSc                                       | kramadan@itg.be           | Department of Clinical Sciences, Institute of Tropical Medicine,                   |  |
|            |               |   |                           | Antwerp, Belgium   |  |
| Tom        | Platteau      | PhD                                       | tplatteau@itg.be          | Department of Clinical Sciences, Institute of Tropical Medicine,                   |  |
|            |               |   |                           | Antwerp, Belgium   |  |
| Karin      | Van Looveren  | BSc                                       | kvanlooveren@itg.be       | Department of Clinical Sciences, Institute of Tropical Medicine,                   |  |
|            |               |   |                           | Antwerp, Belgium   |  |
| Jolien     | Baeyens       | BSc                                       | <u>jbaeyens@itg.be</u>    | Department of Clinical Sciences, Institute of Tropical Medicine,                   |  |
|            |               |   |                           | Antwerp, Belgium   |  |
| Cindy      | Van           |   |                           | Department of Clinical Sciences, Institute of Tropical Medicine,                   |  |
|            | Hoyweghen     |   |                           | Antwerp, Belgium   |  |
| Marianne   | Mangelschots  | Mangelschots BSc <u>mmangelschots@itg</u> |                           | Department of Clinical Sciences, Institute of Tropical Medicine,                   |  |
|            |               |   |                           | Antwerp, Belgium   |  |
| Sandra     | Coppens       | BSc                                       | scoppens@itg.be           | Department of Clinical Sciences, Institute of Tropical Medicine,                   |  |
|            |               |   |                           | Antwerp, Belgium   |  |
| Leo        | Heyndrickx    | MSc                                       | <u>lheyndrickx@itg.be</u> | Department of Clinical Sciences, Institute of Tropical Medicine,                   |  |
|            |               |   |                           | Antwerp, Belgium   |  |
| Johan      | Michiels      | BS  | <u>imichiels@itg.be</u>   | Department of Clinical Sciences, Institute of Tropical Medicine,                   |  |
|            |               |   |                           | Antwerp, Belgium   |  |
| Isab el    | Brosius       | PhD                                       | ibrosius@itg.be           | Department of Clinical Sciences, Institute of Tropical Medicine,                   |  |
|            |               | MD  |                           | Antwerp, Belgium   |  |
| Kevin K.   | Ariën         | PhD                                       | <u>karien@itg.be</u>      | Department of Clinical Sciences, Institute of Tropical Medicine,                   |  |
|            |               |   | +                         | Antwerp, Belgium   |  |
| Johan      | van Griensven | PhD                                       | jvangriensven@itg.be      | Department of Clinical Sciences, Institute of Tropical Medicine,                   |  |
|            |               | MD  |                           | Antwerp, Belgium   |  |
| Marie      | Laga          | PhD                                       | mlaga@itg.be              | Department of Public Health, Institute of Tropical Medicine,                       |  |
|            |               | MD  | 100                       | Antwerp, Belgium   |  |
| Jef        | Vanhamel      | MD  | <u>jvanham el @itg.be</u> | Department of Public Health, Institute of Tropical Medicine,                       |  |
| D          | Mondatalia    | DI-D                                      | house to 64 - h           | Antwerp, Belgium   |  |
| Bea        | Vuylsteke     | PhD<br>MD                                 | bvuylsteke@itg.be         | Department of Public Health, Institute of Tropical Medicine,                       |  |
| Emmanuel   | Bottieau      | PhD                                       | ah atti asu @ita ha       | Antwerp, Belgium  Department of Clinical Sciences, Institute of Tropical Medicine. |  |
| Emmanue    | Bottleau      | MD  | ebottieau@itg.be          | Antwerp, Belgium   |  |
| Patrick    | Coontions     | PhD                                       | psoentjens@itg.be         | Department of Clinical Sciences, Institute of Tropical Medicine,                   |  |
| I attick   | Soent jens    | MD  | padentjena@itg.be         | Antwerp, Belgium   |  |
| Philippe   | Selhorst      | PhD                                       | pselhorts@itg.be          | Department of Clinical Sciences, Institute of Tropical Medicine,                   |  |
| riiiippe   | Selliorst     | PIID                                      | <u>psemorts@itg.be</u>    | Antwerp, Belgium   |  |
| Nicole     | Berens        | MD  | nberens@itg.be            | Department of Clinical Sciences, Institute of Tropical Medicine,                   |  |
| NICOIE     | Dereits       | IVID                                      | inderensæitg.be           | Antwerp, Belgium   |  |
| Saskia     | Van Henten    | MD  | svanhent en @itg.be       | Department of Clinical Sciences, Institute of Tropical Medicine,                   |  |
| Jaskia     | Vali Heliteli | IVID                                      | 3vaimenten witg.be        | Antwerp, Belgium   |  |
| Stefanie   | Bracke        | MD  | sbracke@itg.be            | Department of Clinical Sciences, Institute of Tropical Medicine,                   |  |
| Sterame    | Dideke        | IVID                                      | SDI GONE WITE, DE         | Antwerp, Belgium   |  |
| Thibaut    | Vanbaelen     | MD  | tvanbaelen@itg.be         | Department of Clinical Sciences, Institute of Tropical Medicine,                   |  |
| imbaut     | Valibacieli   | שועו                                      | tvanuacien@itg.ue         | Antwerp, Belgium   |  |
| Antonio    | Mauro         | PhD                                       | arezende@itg.be           | Department of Clinical Sciences, Institute of Tropical Medicine,                   |  |
| ,          | Rezende       | ' ' ' '                                   | arezende@itg.be           | Antwerp, Belgium   |  |
|            | T.CZCIIGC     |   |                           | , and the p, beignann  |  |

<sup>\*</sup>Contributed equally

\$ Corresponding author: Nationalestraat 155, 2000 Antwerp, Belgium; tel +32 (0)3 247 64 44

<sup>\*\*</sup> Contributed equally

Abstract

**Background** 

Monkeypox is transmitted by close contact with symptomatic cases, and those infected are assumed to

be uniformly symptomatic. Evidence of subclinical monkeypox infection is limited to a few

immunological studies which found evidence of immunity against orthopoxviruses in asymptomatic

individuals who were exposed to monkeypox cases. We aimed to assess whether asymptomatic

infections occurred among individuals who underwent sexually transmitted infection (STI) screening in a

large Belgian STI clinic around the start of the 2022 monkeypox epidemic in Belgium.

Methods

Anorectal and oropharyngeal swabs collected for gonorrhoea/chlamydia screening from May 1 until

May 31, 2022 were retrospectively tested by a monkeypox-specific PCR. Cases with a positive PCR result

were recalled to the clinic for case investigation, repeat testing and contact tracing.

**Findings** 

In stored samples from 224 men, we identified three cases with a positive anorectal monkeypox PCR. All

three men denied having had any symptoms in the weeks before and after the sample was taken. None

of them reported exposure to a diagnosed monkeypox case, nor did any of their contacts develop

clinical monkeypox. Follow-up samples were taken 21 to 37 days after the initial sample, by which time

the monkeypox-specific PCR was negative, likely as a consequence of spontaneous clearance of the

3

infection.

<u>Interpretation</u>

The existence of asymptomatic monkeypox infection indicates that the virus might be transmitted to close contacts in the absence of symptoms. Our findings suggest that identification and isolation of

4

symptomatic individuals may not suffice to contain the outbreak.

**Funding:** Institutional funding

Research in context

Evidence before this study

Similar to smallpox, monkeypox is transmitted through close contact with symptomatic cases, and 100%

of those infected are assumed to develop symptoms. These features imply that an outbreak in the

general population tends towards extinction with relatively minor hygienic measures, as observed in

several outbreaks in endemic regions. If, however, asymptomatic transmission occurs, the outbreak

becomes much more difficult to contain.

We searched PubMed and Google Scholar for evidence of asymptomatic human monkeypox, using the

search terms "monkeypox" AND ("asymptomatic" OR "subclinical"), and included peer-reviewed reports

published until June 17, 2022. We identified seven original reports in three different epidemiological

settings which reported indirect, immunological evidence of asymptomatic monkeypox infection in a

small number of people who were exposed to the virus. We did not find any study that provided direct

evidence of the virus in asymptomatic individuals.

Added value of this study

By retrospectively screening clinical samples collected for sexually transmitted infection screening in our

centre throughout May 2022 with a monkeypox-specific PCR, we found evidence of asymptomatic

monkeypox virus infection in three individuals.

Implications of all the available evidence

The existence of asymptomatic monkeypox infection indicates that the virus may be transmitted in the

absence of symptoms. This risk can be further quantified by studying viral dynamics in contacts of

symptomatic and asymptomatic monkeypox cases. Our findings suggest that identification and isolation

5

of symptomatic individuals may not suffice to contain the outbreak.

### Manuscript

## **Introduction**

Monkeypox is a viral disease that is endemic in several African countries.<sup>1</sup> Much of what is known about its natural history stems from outbreaks in the general population in those countries. Based on these data, monkeypox virus (MPXV) is thought to be transmitted through close contact with symptomatic cases.<sup>2</sup> All those infected with MPXV are assumed to develop symptoms<sup>3</sup> and the house hold secondary attack rate is approximately 10%.<sup>2</sup> These features imply that, in the absence of repeated animal-to-human transmission, an outbreak in the general population tends towards extinction with relatively minor hygienic measures, as observed in several outbreaks in endemic regions.<sup>1,4</sup>

The current monkeypox outbreak in non-endemic countries differs from those described earlier, with respect to the affected population and the clinical case picture. Indeed, the current outbreak appears to primarily affect men who have sex with men (MSM).<sup>5</sup> Many present with symptoms that are largely limited to the anogenital region, and some have only minimal symptoms.<sup>6</sup> In addition, some studies found high viral loads in anogenital samples, saliva and semen.<sup>7</sup> This led to the hypothesis that MPXV may be sexually transmitted.<sup>7,8</sup> By June 17, more than 2500 cases have been confirmed in this outbreak which is far more than in previous outbreaks in the general population in endemic countries (https://ourworldindata.org/monkeypox). As such, researchers have raised a number of questions that could explain this extraordinary surge in cases.<sup>9</sup> One of these questions is: could infection with MPXV be asymptomatic and could asymptomatic infections contribute to monkeypox spread?<sup>9</sup> This is a crucial point since if asymptomatic infections could be transmitted onwards, this would mean that identification and isolation of symptomatic cases might not be sufficient to end the outbreak.

Here, we report three asymptomatic MPXV infections which were discovered by retrospectively

screening clinical samples collected for anorectal and oropharyngeal gonorrhoea/chlamydia testing

among men visiting the largest sexually transmitted infection (STI) clinic in Belgium, in May 2022.

<u>Methods</u>

Samples

Between May 1 and May 31, 2022, 237 men underwent testing for anorectal and/or oropharyngeal

gonorrhoea/chlamydia as part of routine care at the HIV/STI clinic of the Institute of Tropical Medicine

Antwerp, Belgium. The sample types tested were anorectal swabs, or opharyngeal swabs, or a

combination of a patient's first-void urine, oropharyngeal swab, and anorectal swab (pooled sample, as

described<sup>10</sup>). Samples were processed with the Abbott Real Time CT/NG assay which includes the Abbott

m2000sp for DNA extractions (Abbott Molecular Des Plaines, Illinois, USA). The original swab samples

and their remnant DNA extracts were frozen (-20°C) or refrigerated (2-8°C), respectively, until

processing in the current study.

Monkeypox-specific PCR

Step 1: Remnant DNA extracts were tested for the presence of MPXV using previously described primer

sets targeting the MPXV-TNF receptor gene. 11 The Applied Biosystems Quantstudio PCR system was

used for PCR amplification.

Step 2: In case of a positive PCR result on a remnant DNA extract, confirmation of the result was sought

on the original sample, as follows. Samples were thawed and spiked with Phocine herpesvirus 1 (PhHV-

1) as process control. DNA extraction was done with Maxwell® Promega, using 300 μL sample input and

75 μL elution volume. DNA extracts were amplified using the same PCR primersets as mentioned above.

Step 3: As a means to verify specificity of the MPXV-PCR, PCR template sizes were analysed by

TapeStation 4150 (Agilent) with the HS D1000 kit.

Case management

Patients with a positive MPXV-PCR result were informed about their diagnosis and recalled to the clinic

for additional case investigation and contact tracing in accordance with WHO guidance. 12 At that time,

follow-up samples were taken for MPXV PCR from the site where the virus was initially detected.

**Ethical considerations:** 

The study protocol was approved by the Institutional Review Board of the Institute of Tropical Medicine

(1600/22). Written informed consent is available from all asymptomatic cases.

Role of the funding source

No external funding.

Results

A total of 225 remnant DNA extracts were available from 224 different men. These included 163 pooled

samples, 60 anorectal swabs and two oropharyngeal swabs. Initial MPXV-PCR (step 1) was positive on

four DNA extracts: three anorectal swabs, and one pooled sample (Table 1). MPXV-PCR after repeat DNA

extraction of the original samples in step 2 confirmed those PCR results on all three anorectal swabs,

and on the anorectal (but not oropharyngeal) swab that constituted the pooled sample. PCR template

size analysis showed a +/- 143 bp DNA fragment on gel electrophoresis for all four samples confirming

specific amplification of the targeted MPXV genomic region.

The four MPXV-positive samples in this study were collected from four men. At the time of sampling,

one of those men suffered from a painful vesicular perianal rash, which was misdiagnosed as a flare-up

of herpes simplex. The remaining three men did not report any symptoms at the time of sampling. According to the institutional guidelines for STI testing among asymptomatic individuals, no specific examination was done at the time of sampling and men self-collected their anorectal swabs at the clinic. Of note, all cases tested negative for *N. gonorrhoeae/C. trachomatis*.

The three asymptomatic monkeypox cases were men between 30 and 50 years old, each with a well-controlled HIV infection and a history of multiple STIs. None of them were vaccinated against smallpox. The three asymptomatic men were recalled to the clinic for further investigation within 21 to 37 days after the initial sampling. At that time, none of the men showed signs or symptoms of monkeypox and all denied having noticed any symptoms during the two months prior or 3 weeks after initial sampling. All three men had condomless sexual intercourse with at least one male partner within a few days to one month before sampling. Two out of three men had sexual contacts while travelling abroad within two weeks before sampling. As far as traceable, none of their partners have reported signs or symptoms of monkeypox. Results of basic laboratory investigations at the time of sampling, including renal and liver function tests, as well as C-reactive protein were normal. Follow-up anorectal swab samples tested PCR negative for MPXV (Table 1).

Table 1: Characteristics of MPXV-positive samples

| Case | Sample<br>type    | Symptoms<br>compatible with MPX<br>at time of sampling | MPXV-PCR result on<br>remnant DNA<br>extract (Ct value) | MPXV-PCR result on original sample (Ct value)                  | Timing of follow-<br>up sample with<br>respect to<br>original sample | MPXV-PCR result<br>on follow-up<br>sample (Ct value) |
|------|-------------------|--|---|--|--|--|
| 1    | Pooled<br>sample  | None   | Positive (27·63)  | Anorectal swab: Positive (26·69); oropharyngeal swab: Negative | +37 days   | Negative   |
| 2    | Anorectal<br>swab | None   | Positive (22-15)  | Positive (20.05)   | +21 days   | Negative   |
| 3    | Anorectal<br>swab | None   | Positive (19·19)  | Positive (17·16)   | +24 days   | Negative   |
| 4    | Anorectal<br>swab | Painful vesicular<br>perianal rash                     | Positive (29·06)  | Positive (27-38)   | NA   | NA   |

Ct = cycle threshold; NA = not applicable

Discussion

We found evidence of asymptomatic MPXV infection in three individuals, in the form of positive PCR results on anorectal samples. Even though the existence of asymptomatic MPXV infection has been suggested by a number of immunological studies in MPXV-exposed individuals, <sup>13–19</sup> this was, to our knowledge, never substantiated by direct detection of the virus. Interestingly, one of the asymptomatic men in our study predates the first detected symptomatic case in Belgium by several days, <sup>20</sup> and could not be epidemiologically linked to any other monkeypox case, nor did he report international travel or participation in mass gatherings. This may indicate that MPXV circulated among asymptomatic

individuals in Belgium before the outbreak was detected.

Due to the retrospective nature of our study, we were unable to assess whether MPXV could also be detected in other body sites of asymptomatic individuals, such as the respiratory tract. MPXV-PCR cycle threshold values in anorectal samples of the asymptomatic men in this study were similar or lower than those in samples taken from typical monkeypox skin lesions that underwent the same testing procedure in our clinic (mean 24.0 + /- standard deviation (sd) 6.7, n = 52 samples, unpublished data). This indicates that the anorectal mucosa of asymptomatic cases may be as infectious as skin lesions of symptomatic cases. Similarly, anorectal cycle threshold values of symptomatic cases in our clinic were in the same range (mean 25.5 + /- sd 7.9, n = 43 samples, unpublished data), which presumably indicates similar viral loads. This would support the hypothesis that MPXV can be transmitted via anal sex, even in the absence of symptoms.

Asymptomatic carriership was previously thought to play a negligible role in the spread of orthopoxviruses. Despite the fact that smallpox virus could be detected in the upper respiratory tract of asymptomatic contacts of smallpox cases, <sup>21</sup> smallpox eradication was primarily, and successfully, based on the identification and isolation of symptomatic cases. <sup>22</sup> Also, during previous monkeypox outbreaks

in endemic countries, the role of asymptomatic carriership was never demonstrated. However, it is

believed that in monkeypox endemic settings, only a fraction of the true caseload is detected due to a

lack of resources to do proper surveillance. Until now, there have been no systematic efforts to detect

asymptomatic carriership of MPXV.

It is possible that in the current outbreak in non-endemic settings, asymptomatic carriership plays a

more substantial role in virus transmission. In endemic settings, patients typically present with a more

generalized rash and transmission occurs mainly within households or health care settings, presumably

through direct contact with skin lesions or droplets.<sup>2</sup> In the current outbreak, the skin eruption often

remains localized at the site of inoculation, and the mode of transmission seems to be sexual.<sup>8</sup> In this

case, asymptomatic carriership, especially with high viral loads in the anal mucosa, could, therefore, be a

significant driver of transmission.

The size of the current outbreak in non-endemic countries is larger than ever documented in the

absence of repeated epizootic events. While this may be explained by the high number of close contacts

among the affected cases, 23 asymptomatic transmission to/from the anorectum in addition to other

body sites may have played a role. Indeed, many reported cases so far had unprotected sex with one or

several casual sex partners. 7,8,24,25 Direct contact with breached anogenital mucosal membranes during

sex may be a previously unrecognised mode of MPXV transmission.<sup>26</sup> Viral transmission in the absence

of noticeable symptoms could explain why self-isolation at symptom onset has been insufficient to halt

the epidemic thus far.

We could not confirm MPXV-PCR positivity of the asymptomatic cases in a second sample taken from a

different body site or at a different time point. By the time the MPXV-PCR result on the stored DNA

extracts was available and the cases returned to the clinic to collect follow-up samples, the infection had

likely been cleared. PCR specificity on the original results was supported by consistent PCR amplicon

electrophoresis (supplementary figure 1). In addition, 98% of the MPXV genome was retrieved by whole genome sequencing (with an average 161.4x sequencing depth) in the original anorectal sample of case 2 (unpublished data). It should be noted that the three asymptomatic men in this study may not have been completely free of signs and symptoms of MPXV at the time of initial sampling, as no clinical or anoscopic examination found place at that time, and symptoms may not have been reported because of recall bias or because small and painless perianal lesions went unnoticed. These findings warrant thorough prospective serological, molecular and epidemiological studies involving monkeypox cases and their contacts. Such studies should elucidate the proportion of asymptomatic cases, to what extent asymptomatic cases are infectious, which body sites contribute to infectiousness, and whether condom use or vaccination could be used to prevent transmission from asymptomatic carriers.

These findings have important consequences for the management of the epidemic. Until the role of asymptomatic transmission is further elucidated, the precautionary principle applies.<sup>23</sup> If we want to stop human-to-human transmission, control measures should be revisited. Firstly, awareness campaigns in the general and high risk populations should include the possibility of asymptomatic transmission among close (sexual) contacts.<sup>23</sup> Secondly, efforts to identify asymptomatic cases should be increased, by contact tracing, and potentially by screening high risk populations. Finally, our data provide additional evidence to introduce vaccination of high risk populations.

Authors' contributions

IDB, MVE, KV, FV, DVDB conceptualized the study. HS performed the testing. IDB & CVD wrote the first

draft of the manuscript with revision by KV & MVE. IDB & CVD analysed the data. CK recontacted the

patients for more epidemiological information. All authors reviewed and approved the final version of

the manuscript.

**Declaration of interests** 

No conflicts of interest to declare.

Acknowledgements

We would like to thank the patients to provide additional information, and all colleagues of the clinical

reference laboratory of the Institute of Tropical Medicine.

Data sharing statement

The data supporting the findings of this publication are retained at the Institute of Tropical Medicine

(ITM), Antwerp and will not be made openly accessible due to ethical and privacy concerns. According to

the ITM research data sharing policy, only fully anonymised data can be shared publicly. The data are

de-identified (using a unique patient code) but not fully anonymised and it is not possible to fully

anonymise them due to the longitudinal nature of the data. Data can however be made available after

approval of a motivated and written request to the ITM at ITMresearchdataaccess@itg.be. The ITM data

access committee will verify if the dataset is suitable for obtaining the study objective and assure that

13

confidentiality and ethical requirements are in place.

### References

- Petersen E, Kantele A, Koopmans M, et al. Human Monkeypox: Epidemiologic and Clinical Characteristics, Diagnosis, and Prevention. *Infect Dis Clin North Am* 2019; **33**: 1027–43.
- Bunge EM, Hoet B, Chen L, et al. The changing epidemiology of human monkeypox—A potential threat? A systematic review. *PLoS Negl Trop Dis* 2022; **16**: 1–20.
- World Health Organization (WHO). Monkeypox Outbreak Toolbox: WHO suggested outbreak case definition. 2022. https://www.who.int/emergencies/outbreak-toolkit/disease-outbreak-toolboxes/monkeypox-outbreak-toolbox (accessed June 20, 2022).
- Jezek Z, Grab B, Dixon H. Stochastic model for interhuman spread of monreypox. *Am J Epidemiol* 1987; **126**: 1082–92.
- Perez Duque M, Ribeiro S, Martins JV, et al. Ongoing monkeypox virus outbreak, Portugal, 29

  April to 23 May 2022. Eurosurveillance 2022; **27**: 1–6.
- Ferraro F, Caraglia A, Rapiti A, *et al.* Letter to the editor : multiple introductions of MPX in Italy from different geographic areas. *Eurosurveillance* 2022; **27**: 1–2.
- Antinori A, Mazzotta V, Vita S, *et al.* Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022. *Euro Surveill* 2022; **27**: 1–6.
- 8 Heskin J, Belfield A, Milne C, *et al.* Transmission of monkeypox virus through sexual contact A novel route of infection. *J Infect* 2022.
- 9 Dye C, Kraemer MUG. Investigating the monkeypox outbreak. *BMJ* 2022; **377**: o1314.
- 10 De Baetselier I, Osbak KK, Smet H, Kenyon CR, Crucitti T. Take three, test one: a cross-sectional

study to evaluate the molecular detection of Chlamydia trachomatis and Neisseria gonorrhoeae in pooled pharyngeal, anorectal and urine samples versus single-site testing among men who have sex with men in Belgium. *Acta Clin Belgica Int J Clin Lab Med* 2020; **75**: 91–5.

- Li Y, Zhao H, Wilkins K, Hughes C, Damon IK. Real-time PCR assays for the specific detection of monkeypox virus West African and Congo Basin strain DNA. *J Virol Methods* 2010; **169**: 223–7.
- World Health Organization (WHO). Surveillance, case investigation and contact tracing for Monkeypox. Interim guidance 22 May 2022.
- Jezek Z, Marennikova SS, Mutumbo M, *et al.* Human monkeypox: A study of 2,510 contacts of 214 patients. *J Infect Dis* 1986; **154**: 551–5.
- 14 Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Human Monkeypox and Other Poxvirus
  Infections of Man. In: Smallpox and its Eradication. 1988: 1287–319.
- Jezek Z, Nakano JH, Arita I, Mutombo M, Szczeniowski M, Dunn C. Serological survey for human monkeypox infections in a selected population in Zaire. *J Trop Med Hyg* 1987; **90**: 31–8.
- Hammarlund E, Lewis MW, Carter S V., *et al.* Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. *Nat Med* 2005; **11**: 1005–11.
- 17 Fleischauer AT, Kile JC, Davidson M, et al. Evaluation of human-to-human transmission of monkeypox from infected patients to health care workers. Clin Infect Dis 2005; **40**: 689–94.
- 18 Karem KL, Reynolds M, Hughes C, et al. Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection. Clin Vaccine Immunol 2007; **14**: 1318–27.
- 19 Guagliardo SAJ, Monroe B, Moundjoa C, et al. Asymptomatic orthopoxvirus circulation in humans

- in the wake of a monkeypox outbreak among chimpanzees in Cameroon. *Am J Trop Med Hyg* 2020; **102**: 206–12.
- Selhorst P, Rezende AM, de Block T, *et al.* Belgian case of Monkeypox virus linked to outbreak in Portugal. 2022. https://virological.org/t/belgian-case-of-monkeypox-virus-linked-to-outbreak-in-portugal/801 (accessed June 20, 2022).
- Sarkar JK, Mitra AC, Mukherjee MK, De SK. Virus excretion in smallpox. *Bull World Health Organ* 1973; **48**: 523–7.
- Fenner F. The global eradication of smallpox. *Med J Aust* 1980; **1**: 455–6.
- Pan D, Sze S, Nazareth J, *et al.* Monkeypox in the UK: arguments for a broader case definition. *Lancet* 2022; **6736**: 1–2.
- Hammerschlag Y, Macleod G, Papadakis G, et al. Monkeypox infection presenting as genital rash,

  Australia, May 2022. Eurosurveillance 2022; 27: 1–4.
- de Nicolas-Ruanes B, Vivancos M, Azcarraga-Llobet C, et al. Monkeypox virus case with maculopapular exanthem and proctitis during the Spanish outbreak in 2022. *J Eur Acad Dermatology Venereol* 2022.
- Miura F, Ewijk CE Van, Backer JA, Xiridou M, Franz E, Coul E Op De. Estimated incubation period for monkeypox cases confirmed in the Netherlands , May 2022. *Eurosurveillance* 2022; **27**: 1–4.